This may make a lot of sense. But will the EPIC Act move? My worry is that this will probably be viewed being a give-back to your biopharma market equally as cost controls are beginning to take outcome thus leading to rejection of this bill. An even bigger get worried could well be that Congress would repair the “smaller molecule penalty” by al